Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer

Lancet

Volumn 350, Issue 9084, 1997, Pages 1047-1059

  Calle, E E ^a   Heath Jr , C W ^a   Coates, R J ^b   Liff, J M ^b   Franceschi, S ^c   Talamini, R ^c   Chantarakul, N ^d   Koetsawang, S ^d   Rachawat, D ^d   Morabia, A ^e   Schuman, L ^e   Stewart, W ^e   Szklo, M ^e   Bain, C ^f   Schofield, F ^f   Siskind, V ^f   Band, P ^g   Coldman, A J ^g   Gallagher, R P ^g   Hislop, T G ^g   Yang, P ^g   Duffy, S W ^h   Kolonel, L M ⁱ   Nomura, A M Y ⁱ   Oberle, M W ^j   Ory, H W ^j   Peterson, H B ^j   Wilson, H G ^j   Wingo, P A ^j   Ebeling, K ^k   Kunde, D ^k   Nishan, P ^k   Colditz, G ^l   Martin, N ^m   Pardthaisong, T ^m   Silpisornkosol, S ^m   Theetranont, C ^m   Boosiri, B ⁿ   Chutivongse, S ⁿ   Jimakorn, P ⁿ   Virutamasen, P ⁿ   Wongsrichanalai, C ⁿ   McMichael, A J ^o   Rohan, T ^o   Ewertz, M ^p   Paul, C ^q   Skegg, D C G ^q   Spears, G F S ^q   Boyle, P ^r   Evstifeeva, M ^r   Daling, J R ^s   Hutchinson, W B ^s   Malone, K ^s   Noonan, E A ^s   Stanford, J L ^s   Thomas, D B ^s   Weiss, N S ^s   White, E ^s   Andrieu, N ^t   Bramond A ^t   Clavel, F ^t   Gairard, B ^t   Lansac, J ^t   Piana, L ^t   Renaud, R ^t   Fine, S R P ^u   Cuevas, H R ^v   Ontiveros, P ^v   Palet, A ^v   Salazar, S B ^v   Aristizabel, N ^w   Cuadros, A ^w   Bachelot, A ^x   Le M G ^x   Deacon, J ^y   Peto, J ^y   Taylor, C N ^y   Alfandary, E ^z   Modan, B ^z   Ron, E ^z   Friedman, G D ^aa   Hiatt, R A ^aa   Bishop, T ^ab   Kosmelj, J ^ac   Primic Zakelj, M ^ac   Ravnihar, B ^ac   Stare, J ^ac   Beeson, W L ^ad   Fraser, G ^ad   Bulbrook, R D ^ab   Cuzick, J ^ab   Fentiman, I S ^ab   Hayward, J L ^ab   Wang, D Y ^ab   Hanson, R L ^ae   Leske, M C ^ae   Mahoney, M C ^ae   Nasca, P C ^ae   Varma, A O ^ae   Weinstein, A L ^ae   Moller, T R ^af   Olsson, H ^af   Ranstam, J ^af   Goldbohm, R A ^ag   van den Brandt, P A ^ag   Apelo, R A ^ah   Baens, J ^ah   de la Cruz, J R ^ah   Javier, B ^ah   Lacaya, L B ^ah   Ngelangel, C A ^ah   La Vecchia, C ^ai   Negri, E ^ai   Marubini, E ^aj   Ferraroni, M ^ak   Gerber, M ^t   Richardson, S ^t   Segala, C ^t   Gatei, D ^al   Kenya, P ^al   Kungu, A ^al   Mati, J G ^al   Brinton, L A ^am   Hoover, R ^am   Schairer, C ^am   Spirtas, R ^an   Lee, H P ^ao   Rookus, M A ^ap   van Leeuwen, F E ^ap   Schoenberg, J A ^aq   Gammon, M D ^ar   Clarke, E A ^as   Jones, L ^u   McPherson, K ^u,bk   Neil, A ^u   Vessey, M ^u   Yeates, D ^u   Beral, V ^at   Bull, D ^at   Crossley, B ^at   Hermon, C ^at   Jones, S ^at   Key, T ^at   Lewis, C ^at   Reeves, G ^at   Collins, R ^au   Doll, R ^au   Peto, R ^au   Hannaford, P ^av   Kay, C ^av   Rosero Bixby, L ^aw   Yuan, J M ^ax   Wei, H Y ^ay   Yun, T ^ay   Zhiheng, C ^ay   Berry, G ^u   Cooper Booth, J ^u   Jelihovsky, T ^u   MacLennan, R ^u   Shearman, R ^u   Wang, Q S ^az   Baines, C J ^u   Miller, A B ^u   Wall, C ^u   Lund, E ^ba   Stalsberg, H ^ba   Dabancens, A ^bb   Martinez, L ^bb   Molina, R ^bb   Salas, O ^bb   Alexander, F E ^bc   Hulka, B S ^bd   Chilvers, C E D ^be   Bernstein, L ^bf   Haile, R W ^bf   Paganini Hill, A ^bf   Pike, M C ^bf   Ross, R K ^bf   Ursin, G ^bf   Yu, M C ^bf   Longnecker, M P ^bg   Newcomb, P ^bg   Farley, T M N ^bh   Holck, S ^bh   Meirik, O ^bh   Adami, H O ^bi   Bergkvist, R ^bi   Persson, I ^bi   Levi, F ^bj   Mabuchi, K ^bl   Preston, D ^bl   Katsouyanni, K ^bm   Trichopoulou, A ^bm   Trichopoulos, D ^bm   Bergkvist, L ^u   more..

^a AMERICAN CANCER SOCIETY   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d MAHIDOL UNIVERSITY   (Thailand)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h MRC BIOSTATISTICS UNIT   (United Kingdom)

ⁱ UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k Central Institute of Cancer Research   (Germany)

^l HARVARD MEDICAL SCHOOL   (United States)

^m CHIANG MAI UNIVERSITY   (Thailand)

ⁿ CHULALONGKORN UNIVERSITY   (Thailand)

^o CSIRO   (Australia)

^p DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^q UNIVERSITY OF OTAGO   (New Zealand)

^r EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^s Fred Hutchinson Cancer Research Center   (United States)

^t INSERM   (France)

^u Holly Lodge ^*

^v SECRETARÍA DE SALUD   (Mexico)

^w Hospital Universitario

^x INSTITUT GUSTAVE ROUSSY   (France)

^y INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^z SHEBA MEDICAL CENTER   (Israel)

^aa KAISER PERMANENTE   (United States)

^ab IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^ac INSTITUTE OF ONCOLOGY   (Slovenia)

^ad LOMA LINDA UNIVERSITY   (United States)

^ae Long Island Breast Cancer Study   (United States)

^af LUND UNIVERSITY HOSPITAL   (Sweden)

^ag MAASTRICHT UNIVERSITY   (Netherlands)

^ah UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^ai Istituto 'Mario Negri'   (Philippines)

^aj Istituto Nazionale Tumori   (Philippines)

^ak Istituto di Statistica Medica e Biometria   (Philippines)

^al Nairobi Centre for Research in Reproduction   (Kenya)

^am NATIONAL CANCER INSTITUTE   (United States)

^an Institute of Child Health and Human Development   (United States)

^ao NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^ap NETHERLANDS CANCER INSTITUTE   (Netherlands)

^aq New Jersey State Department of Health   (United States)

^ar Netherlands Cancer Institute ^*  (United States)

^as Ontario Cancer Treatment and Research Foundation   (Canada)

^at UNIVERSITY OF OXFORD   (United Kingdom)

^au CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^av ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^aw UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^ax SHANGHAI CANCER INSTITUTE   (China)

^ay SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^az KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^ba UNIVERSITY OF TROMSØ   (Norway)

^bb UNIVERSITY OF CHILE   (Chile)

^bc UNIVERSITY OF EDINBURGH   (United Kingdom)

^bd IL   (United States)

^be UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^bf UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^bg UNIVERSITY OF WISCONSIN   (United States)

^bh WORLD HEALTH ORGANIZATION   (Switzerland)

^bi KAROLINSKA INSTITUTE   (Sweden)

^bj UNIVERSITY OF LAUSANNE   (Switzerland)

^bk LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^bl RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^bm UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CLINICAL TRIAL; EUROPE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; META ANALYSIS; NORMAL HUMAN; NORTH AMERICA; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0030843969     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)08233-0     Document Type: Article

References (66)

1. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243:1635-39.
2. Brinton LA, Hoover RM, Szklo M, Fraumeni JF. Menopausal estrogen use and risk of breast cancer. Cancer 1981; 47: 2517-22.
3. Thomas DB, Persing JP, Hutchinson WB. Exogenous oestrogens and other risk factors for breast cancer in women with benign breast diseases. J Natl Cancer Inst 1982; 69: 1017-25.
4. Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer: final report of an epidemiologic study. Br J Cancer 1983; 47: 455-62.
5. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 1984; 54: 139-44.
6. Talamini R, La Vecchia C, Franceschi S, et al. Reproductive and hormonal factors and breast cancer in a Northern Italian population. Int J Epidemiol 1985; 14: 70-74.
7. Hislop TG, Coldman AJ, Elwood JM, Brauer G, Kan L. Childhood and recent eating patterns and risk of breast cancer. Cancer Detect Prevent 1986; 9: 47-58.
8. Nomura AMY, Kolonel LN, Hirohata T, Lee J. The association of replacement estrogens with breast cancer. Int J Cancer 1986; 37: 49-53.
9. Alexander FE, Roberts MM, Huggins A. Risk factors for breast cancer with applications to selection for the prevalence screen. J Epidemiol Commun Health 1987; 41: 101-06.
10. Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987; 79: 1247-54.
11. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 1987; 56: 653-60.
12. Wang DY, De Stavola BL, Bulbrook RD, et al. The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Clin Oncol 1987; 23: 1541-48.
13. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257: 209-15.
14. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42: 832-38.
15. Kay CR, Hannaford PC. Breast cancer and the pill - a further report from the Royal College of General Practitioners' Oral Contraception Study. Br J Cancer 1988; 58: 675-80.
16. Marubini E, Decarli A, Costa A, et al. The relationship of dietary intake and serum levels of retinol and beta-carotene with breast cancer: results of a case-control study. Cancer 1988; 61: 173-80.
17. Ravnihar B, Primic Zakelj M, Kosmelj K, Stare J. A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. Neoplasma 1988: 35: 109-21.
18. Rohan TE, McMichael AJ. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust 1988; 148: 217-21.
19. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-97.
20. Mills PK, Beeson WL, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in seventh-day adventists. Cancer 1989; 64: 591-97.
21. Siskind V, Schofield F, Rice D, Bain C. Breast cancer and breast feeding: results from an Australian case-control study. Am J Epidemiol 1989; 130: 229-36.
22. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989; 59: 613-17.
23. Paul C, Skegg DCG, Spears GFS. Oral contraceptives and risk of breast cancer. Int J Cancer 1990; 46: 366-73.
24. Hulka BS, Chambless LE, Deubner DC, Wilkinson WE. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 1992; 143: 638-44.
25. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and combined oral contraceptives: results from a multinational study. Br J Cancer 1990; 61: 110-19.
26. Segala C, Gerber M, Richardson S. The pattern of risk factors for breast cancer in a Southern France population: interest for a stratified analysis by age at diagnosis. Br J Cancer 1991; 64: 919-25.
27. La Vecchia C, Negri E, Franceschi S, Parazzini F. Non contraceptive oestrogens and breast cancer. Int J Cancer 1992; 50: 161-62.
28. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study I: breast cancer detection and death rates among women aged 40-49 years. Can Med Assoc J 1992: 147: 1459-76.
29. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol 1991; 134: 1386-95.
30. Ursin G, Aragaki CC, Paganini-Hill A, Siemiatycki J, Thompson WD, Haile RW. Oral contraceptives and premenopausal bilateral breast cancer: a case-control study. Epidemiology 1992; 3: 414-19.
31. Yang CP, Daling JR, Band PR,Gallagher RP, White E, Weiss NS. Non contraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992; 3: 475-79.
32. Morabia A, Szklo M, Stewart W, Schuman L, Thomas DB. Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighbourhood controls. Prevent Med 1993; 22: 178-86.
33. Weinstein AL, Mahoney MC, Nasca PC, Hanson RL, Leske MC, Varma AO. Oestrogen replacement therapy and breast cancer risk: a case-control study. Int J Epidemiol 1993; 22: 781-89.
34. Ngelangel CA, Lacaya LB, Cordero C, Laudico AV. Risk factors for breast cancer among Filipino women. Phil J Intern Med 1994; 32: 231-36.
35. Rookus MA, van Leeuwen FE, for the Netherlands Oral Contraceptives and Breast Cancer Study Group. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet 1994; 344: 844-51.
36. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5: 491-500.
37. White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young US women in relation to oral contraceptive use. J Natl Cancer Inst 1994; 86: 505-14.
38. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995; 87: 827-35.
39. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93.
40. Folsom AR, Mink PJ, Sellers TA, Hong C-P, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995; 85: 1128-32.
41. La Vecchia C, Negri E, Franceschi S, et al. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995: 72: 244-48.
42. Lipworth L, Katsouyanni K, Stuver S, Samoli E, Hankinson SE, Trichopoulos D. Oral contraceptives, menopausal estrogens, and the risk of breast cancer: a case-control study in Greece. Int J Cancer 1995; 62: 548-51.
43. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995; 142: 788-95.
44. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormones and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control 1995; 6: 416-24.
45. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-42.
46. Levi F, Lucchini F, Pasche C, La Vecchia C. Oral contraceptives, menopausal hormone replacement therapy and breast cancer risk. Eur J Cancer Prevent 1996; 5: 259-66.
47. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449-57.
48. Goodman MT, Cologne J, Moriwaki H, Vaeth M, Mabuchi K. Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic-bomb survivors. Prevent Med 1997; 26: 144-53.
49. Thomas HV, Key TJ, Allen DS, et al. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1997; 89: 396-97.
50. Sartwell PE, Arthes FG, Tonascia JA. Exogenous hormones, reproductive history and breast cancer. J Natl Cancer Inst 1977; 59: 1589-92.
51. Wynder EL, MacCornack FA, Stellman SD. The epidemiology of breast cancer in 785 United States caucasian women. Cancer 1978; 41: 2341-54.
52. Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979; 15: 395-405.
53. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst 1981; 67: 815-20.
54. Kelsey JL, Holford TR, White C, Mayer ES, Kilty SE, Acheson RM. Exogenous oestrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67: 327-33.
55. Sherman B, Wallace R, Bean J. Estrogen use and breast cancer: interaction with body mass. Cancer 1983; 51: 1527-31.
56. Horwitz RI, Stewart KR. Effect of clinical features on the association of estrogens and breast cancer. Am J Med 1984; 76: 192-98.
57. McDonald JA, Weiss NS, Daling JR, Francis AM, Polissar L. Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 1986; 7: 193-99.
58. Brownson RC, Blackwell CW, Pearson DK, Reynolds RD, Richens JW, Papermaster BW. Risk of breast cancer in relation to cigarette smoking. Arch Intern Med 1988; 148: 140-44.
59. Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992; 84: 1575-82.
60. Kaufman DW, Miller DR, Rosenberg L, et al. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984; 252: 63-67.
61. Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991; 134: 1375-85.
62. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
63. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54 (suppl): S1-106.
64. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient- I: introduction and design. Br J Cancer 1976; 34: 585-612.
65. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient- II: analysis and examples. Br J Cancer 1977; 35: 1-39.
66. Easton DF, Peto J, Babiker AGAG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 1991; 10: 1025-35.